FDA
-
-
-
-
-
-
-
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
-
-
-
-
-
-
-
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
-
-
-
-
-
-
-
PharmaTher receives FDA approval for ketamine product KETARx
-
-
-
-
-
-
-
PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
-
-
-
-
-
-
-
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
-
-
-
-
-
-
-
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
-
-
-
-
-
-
-
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
-
326,558 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

